cis-Diamminedichloroplatinum (II) (cis-DDP), the antitumor drug, is cytotoxic in vitro primarily by binding to DNA and disrupting its normal functions. We have studied cis-DDP modification of DNA in nucleated peripheral blood cells (buffy coat cells) of testicular and ovarian cancer patients receiving cis-DDP chemotherapy, and of untreated controls. Using a highly sensitive enzyme-linked immunosorbent assay (ELISA) with an antiserum specific for the bidentate intrastrand N7-deoxyguanosine adduct, blood cell DNA was assayed at multiple times during courses of cis-DDP treatment. A total of 138 samples were analyzed from 54 individuals. Of these, all samples from 18 untreated controls were negative, while 44 out of 120 samples from cis-DDP patients were positive. Testicular and ovarian cancer patients receiving chemotherapy on the first course, and given cis-DDP in 21-or 28-day cycles (five days of drug infusion followed by two or three drug-free weeks) accumulated cis-DDP-DNA adducts in blood cell DNA as a function of dose. Patients receiving their first course of cis-DDP on 56-day cycles and those given high doses of this drug after failing other chemotherapy showed much slower adduct accumulation than patients receiving their first course on 21-or 28-day cycles. Adduct accumulation, in positive patients, occurred both as a function of total cumulative dose and with increasing cycle number, suggesting that adduct removal took at least a month in these patients. Disease response data, available on 33 of the 45 cis-DDP patients, suggested that individuals who failed cis-DDP chemotherapy were less likely to form measurable cis-DDP-DNA adducts than those who responded. Characteristics of cis-DDP-DNA adduct formation and removal in rat tissues have indicated that both the dose-response phenomenon and slow adduct removal occur in rats exposed to cis-DDP. It is anticipated that studies with patients and animal models will lead to a greater understanding of the mechanisms underlying cis-DDP tumoricidal activity and may lead to more effective and less toxic drug treatment methods.
Introduction cis-Diamminedichloroplatinum (II) (cis-DDP) is one of the most effective tumoricidal drugs currently available. In combination with other drugs, it is responsible for cure rates of approximately 80% in testicular carcinoma (1) and results in clinical complete response rates of approximately 65% in advanced ovarian cancer patients (2) . Although the mechanism of therapeutic efficacy is not completely understood, the cytocidal activity of cis-DDP has long been associated with effects on DNA (3) (4) (5) , and damage in the form of specific adducts has been characterized chemically (6) (7) (8) . This includes primarily mono-adducts on deoxyguanosine (dG), intrastrand adducts between two dGs with or without an intervening base, and interstrand DNA-DNA cross-*National Cancer Institute, National Institutes of Health, Bethesda, MD 20205. links. Thus, it appeared possible that adducts might form in cancer patients treated with cis-DDP, and that determination of such cis-DDP-DNA adducts might provide a useful model in which to investigate the biological consequences of adduct formation in humans. Such a study would be attractive for a variety of reasons: drug dosages and exposure times would be known precisely, the DNA of peripheral blood would be readily obtainable, measurable adducts could be correlated with clinical course and the ensuing information might assist the clinician in management of the neoplastic disease. In addition, since secondary tumors may eventually occur among the individuals currently undergoing cis-DDPinduced cures, such data might be useful in exploring the role of DNA adduct formation during human tumorigenesis.
Recently, the utilization of antibodies specific for carcinogen-DNA adducts has made possible the development of sensitive immunoassays able to detect a few hundred adducts per mammalian genome, or about one adduct in 108 nucleotides (9) . The highly sensitive and specific nature of this technology, coupled with the lack of a requirement for a radioactive sample, has made it an attractive candidate for attempting to monitor DNA adducts in the human population. A major adduct formed in vivo subsequent to the interaction between cis-DDP and DNA is an intrastrand bidentate adduct on adjacent deoxyguanosines [Eq. (1) ], where linkage is through N7 positions by displacement of the cis-chlorides (d[GpG]-N7-diammnineplatinum) (7) . An antiserum elicited against
Bidentate Intrastrand N7 Adduct (1) calf-thymus DNA modified with cis-DDP in vitro (4.4 adducts per 100 nucleotides) has been shown to have specificity directed primarily towards this intrastrand bidentate adduct and to recognize DNAs from cultured cells and tissues of intact animals exposed to cis-DDP (10, 11) . The present study demonstrates that the intrastrand bidentate adduct is present in the DNA of nucleated peripheral blood cells of cancer patients given cis-DDP chemotherapy, and in tissues of rats to cis-DDP by intravenous injections.
Methods cis-DDP Administration to Patients and Rodents
Individuals studied were being treated for either ovarian or testicular cancer by the Medicine Branch of the National Cancer Institute. These patients were given cis-DDP therapy as part of approved experimental protocols (see Table 1 
Results

Antibody Specificity and Assay Sensitivity
The antiserum utilized in these studies has previously been shown to be specific for adducts of cis-but not trans-DDP-DNA formed in cultured cells and intact animals (10) . This antiserum fails to recognize cis-DDP alone (Fig. 1A) , DNA alone (Fig. 1B) , and the DNA interstrand crosslinks determined by alkaline elution (5) . Through the use of a highly sensitive competitive ELISA (Fig. 1A) to which 50 ,ug samples of DNA can be added per microtiter plate well, it is possible to measure attomole (10-0' mole) quantities of cis-DDP-DNA adduct per microgram of DNA. A series of studies with homopolymers and heteropolymers modified with cis-DDP, and calf-thymus DNAs modified with various platinum drug analogs have indicated that the antibody specificity is directed towards d(GpG)-N7-diammineplatinum, a bidentate adduct with cis covalent bonds on the same strand of DNA (11 Figure   1B . It is evident that the antibody recognized the patient DNA and not the DNA from the normal volunteer. This constituted the first evidence that measurable levels of cis-DDP-DNA intrastrand adducts are formed in individuals receiving cis-DDP chemotherapy. The antibody recognition is not as complete as with the immunogen cis-DDP-DNA since the slope of the competition curve (Fig. 1B) is more shallow than the standard curve (Fig. 1A) . This observation suggests that other types of cis-DDP-DNA adducts (possibly mono-or G-X-G adducts) may be formed simultaneously, resulting in lower affinity antibody binding for certain DNA regions and an overall decrease in ability to compete, as compared to the immunogen DNA. Table 1 shows a summary of the results from ELISAs of 138 blood DNA samples obtained from 54 individuals. Most patients were studied during more than one cycle of chemotherapy, and most samples were obtained after the 5-day drug infusion (the morning of day 6). This time was chosen because early results demonstrated that the proportion of positive samples increased towards the end of the infusion. Studies with animal models reported here show interesting parallels with the human data. Rat kidney was chosen as the most relevant tissue because of the significant kidney toxicity noted in patients and animal models. Attempts to measure adducts in rat blood were not successful because of the small yield of DNA. In performing the studies reported here we observed large interanimal variability in cis-DDP-DNA adduct formation among inbred animals in the same group. This variability may be related to feeding cycles since overnight fasting has reduced the variability in subsequent experiments (data not shown). It is clear, however, that cis-DDP-DNA adducts are formed in rat kidney in a dose-dependent fashion, and that these adducts are highly persistent, since little or no removal took place within the first 2 weeks after exposure. These studies are being extended to include rats bearing the Walker 256 sarcoma and nude mice carrying cis-DDP sensitive and resistent human ovarian tumors. In tumor-bearing animal models it may be possible to determine whether or not specific adduct levels are associated with antitumorigenic efficacy in both kidney and neoplasm, and if manipulation of drug administration may modulate adduct formation in tumor tissues.
Of the many possible sequelae cis-DDP may produce in humans, one of the most ominous is the generation of second malignancies, reports of which have been recently published (14, 15) . It is possible that the slow rate of intrastrand adduct removal contributes to the chemotherapeutic potency of cis-DDP and also that this adduct persistency may be related to the possible development of treatment-induced neoplasia. Adduct persistence is known to be associated with tumorigenesis in animal models. For example, in neonatal rats exposed to ethylnitrosourea, a neurooncogenic effect in brain tissue has been shown to correlate directly with the slow rate of repair of the 06-ethyl-dG adduct formed by ethylnitrosourea (16) . If reports of cis-DDP-related neoplasia become more frequent, a difficult therapeutic dilemma may ensue, and data generated in studies such as ours may be useful in determining if adduct accumulation is associated with risk of second malignancy. It is hoped that the ability to monitor cis-DDP-DNA adducts may allow the clinician to titrate cis-DDP for chemotherapeutic potency while minimizing immediate toxicity and the potential threat of second malignancy. Studies utilizing the ELISA to quantitate adducts in animal models may become a useful adjunct for designing drug treatment protocols and for elucidating mechanisms underlying drug efficacy.
